RxDoctor Payments Data

Greg Ehgartner, DO

Internal Medicine · Camp Hill, PANPI 1346230158

Payments from drug & device makers

$14,231in general payments, 2019–2025

Across 988 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$913
  • Amgen$894
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$14,14899%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,231 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$163,963
Medicare patients
621
Services billed
1,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban419$243,439
JardianceEmpagliflozin160$175,851
XareltoRivaroxaban113$95,286
OzempicSemaglutide36$65,348
JanuviaSitagliptin Phosphate74$60,747
TrulicityDulaglutide22$52,120
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$41,751
MounjaroTirzepatide27$37,537
RybelsusSemaglutide27$32,860
Repatha SureclickEvolocumab22$23,460
JanumetSitagliptin Phos/Metformin Hcl18$22,789
Atorvastatin Calcium969$17,866
MyrbetriqMirabegron38$13,844
RexultiBrexpiprazole17$12,399
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$12,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$875$243,439419 claims
Boehringer IngelheimJardiance$473$175,851160 claims
Novo NordiskOzempic, Rybelsus$1,881$98,20963 claims
Johnson & JohnsonXarelto$245$95,286113 claims
Lilly USA, LLCTrulicity, Mounjaro$1,216$89,65749 claims
MerckJanuvia, Janumet$294$83,53692 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,321$58,34695 claims
Astellas Pharma US IncMyrbetriq$169$13,84438 claims
Otsuka America Pharmaceutical, Inc.Rexulti$73$12,39917 claims
AbbVieLinzess$1,780$11,01015 claims
Sanofi-aventis U.S. LLCMultaq$58$10,26322 claims
Almatica Pharma LLCSertraline Hcl$39$7,728416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →